Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor

Br J Haematol. 2019 Jun;185(5):961-966. doi: 10.1111/bjh.15666. Epub 2018 Nov 27.

¹ University of Texas MD Anderson Cancer Center, Houston, TX.
² Department of Medicine, College of Medicine, and Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH.
³ Dana-Farber Cancer Institute, Boston, MA.
⁴ Weill Cornell Medicine, New York, NY.
⁵ Georgetown University Hospital, Washington, DC.
⁶ Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
⁷ University of California Los Angeles, Los Angeles, CA.
⁸ Emory University School of Medicine, Atlanta, GA.
⁹ AbbVie Inc., North Chicago, IL.
¹⁰ University of California San Diego, San Diego, CA.

No abstract available

Keywords: B-cell receptor signalling pathway inhibitor; chronic lymphocytic leukaemia; refractory; relapsed; venetoclax.

Publication types